ASCO 2026 plenary data establishes daraxonrasib as the new second-line standard of care for advanced pancreatic tumors.

At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Ladies and gentlemen, thank you for standing by. Welcome to the Cardiff Oncology ASCO Data Presentation Conference Call. [Operator Instructions] Please be advised that today's conference is being ...

Structured exercise program following adjuvant chemotherapy for colon cancer: A cost-utility analysis of the CHALLENGE trial. Circulating tumor DNA (ctDNA) clearance as an early indicator of sotorasib ...

MARONDERA, June 2 (NewsDay Live) — Scores of small-scale traders in Marondera were left counting their losses on Tuesday after the Municipality of Marondera demolished illegal structures erected along ...

A shift in the way people think about and treat pancreatic cancer could be on the horizon based on positive results from the pivotal randomized Phase III RASolute 302 trial comparing daraxonrasib to ...

- The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program - - 30 mg onvansertib + ...

Hotels across Ras Al Khaimah are reporting strong occupancy ahead of Eid Al Adha, driven by rising demand from UAE residents opting for short-haul staycations within driving distance, as travellers ...

Hadron Energy has cleared an early milestone in its effort to commercialize small-scale nuclear ...

In the human body, the boundary between health and severe illness can be microscopic. For decades, molecular scientists have grappled with a frustrating biological reality: The proteins driving ...